Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen Inc. (OPGN), now named CapForce Inc., reports developments tied to its repositioning from a precision medicine diagnostics company toward digital investment banking and financial technology. Recent company updates cover the name change, material agreements, capital actions, shareholder voting matters and governance decisions.
The company's historical news also includes operating and financial results for its former molecular diagnostics and bioinformatics business, including Unyvero systems and ARESdb-related assets. Other recurring items include reverse stock split actions, securities purchase arrangements, subsidiary insolvency developments and transitions affecting legacy commercial diagnostics operations.
OpGen announced significant clinical results from its Unyvero Hospitalized Pneumonia (HPN) panel, demonstrating a 45.1% reduction in inappropriate antibiotic therapy and an average therapy duration decrease of 39 hours. The study involving 208 patients showed a threefold increase in avoiding inappropriate therapy for those diagnosed using Unyvero. Results presented at the European Respiratory Society conference reflect the tool's effectiveness in managing pneumonia cases at risk for Gram-negative bacteria, underscoring its potential in antibiotic stewardship.
OpGen reported a total revenue of approximately $0.8 million for Q2 2021, a 32% decline compared to Q2 2020's $1.2 million. This decrease is attributed to the exit from the FISH business and the conclusion of prior R&D collaborations. Operating expenses decreased to $7.0 million from $7.7 million year-over-year. Despite net losses of $7.1 million ($0.19 per share), cash reserves improved significantly to $31.2 million, up from $13.4 million at the end of 2020. Key milestones include the assembly of Unyvero A30 RQ analyzers and progress in FDA submissions.
OpGen, Inc. (Nasdaq: OPGN) announced it will withdraw Proposal 2 from its Definitive Proxy Statement regarding an increase in authorized shares, leading to the cancellation of the reconvened Annual Meeting set for August 5, 2021. This decision follows the approval of all other proposals during the Annual Meeting on June 9, 2021. The company is exploring alternatives for financing its future growth. OpGen focuses on precision medicine through molecular diagnostics and aims to improve treatment outcomes for infectious diseases.
OpGen, Inc. (NASDAQ: OPGN) will report its Q2 2021 financial results and provide a business update on August 12, 2021, after U.S. market close. The management team will host a live conference call at 4:30 p.m. ET to discuss these results and business activities. Interested parties may join via the U.S. or International dial-in numbers provided or through a webcast link. A replay will be accessible until August 26, 2021. OpGen focuses on precision medicine and developing molecular diagnostics for infectious diseases to improve patient outcomes.
OpGen has announced the completion of assembly for 10 pre-series Unyvero A30 RQ analyzers by its subsidiary Curetis. This marks a significant milestone as these instruments will enter final verification and validation testing. The A30 RQ platform aims to provide rapid, multiplexed testing from various clinical specimens, yielding results in as little as 30 minutes. Future product developments are being evaluated, and the platform is open for licensing opportunities, enhancing OpGen's strategic partnerships.
OpGen, Inc. has adjourned its annual stockholders meeting to allow additional time for votes on Proposal 2, which seeks to increase the authorized shares of common stock. The meeting will resume on August 5, 2021, at 10:00 AM ET. CEO Oliver Schacht emphasized the importance of this proposal for the company's future and potential financing needs, noting a strong cash position of $39.4 million as of Q1 2021. However, at least 66.67% of shares must vote in favor for it to pass. The Board is also exploring alternative financing options.
OpGen, Inc. (Nasdaq: OPGN) shared promising prospective clinical data on its Unyvero LRT BAL panel during a recent webinar. The panel demonstrated its ability to adjust antimicrobial therapy in 53% of ICU patients, providing results 21 hours faster than conventional tests. With 99.2% concordance for organism targets and significant detection of pneumonia-causing bacteria, the panel reduces unnecessary antibiotic use and associated adverse effects. Additionally, the Acuitas AMR Gene Panel showcased potential in infection control at the World Microbe Forum, further underscoring OpGen's commitment to combating antimicrobial resistance.
OpGen, Inc. (Nasdaq: OPGN) announced promising preliminary data from Ares Genetics’ multicenter validation of long-read nanopore sequencing. The results showed 100% accuracy in pathogen identification, with up to 97% accuracy for antimicrobial resistance (AMR) markers. Ares Genetics aims to enhance AMR surveillance through cost-effective and efficient sequencing technologies, particularly in low to mid-income countries, where AMR outbreaks are a rising concern. The AREScloud software will facilitate data analysis and interpretation, supporting clinical adoption and accurate diagnostics.
OpGen, Inc. (Nasdaq: OPGN) announced the adjournment of its 2021 Annual Stockholders Meeting specifically for Proposal 2, which seeks to increase the company's authorized shares from 60 million to 110 million. The proposal received favorable initial votes, with over two-thirds in support from approximately 43% of voting shareholders. The meeting will resume on July 7, 2021. CEO Oliver Schacht emphasized the necessity of this proposal for the company's growth and flexibility, especially in managing long-term debt and raising capital. OpGen held $39.4 million in cash at Q1-end 2021.
OpGen announced its subsidiary Ares Genetics is developing a culture-free genomic assay for antimicrobial resistance (AMR) surveillance. The Ares universal pathogenome assay (ARESupa) aims to surpass limitations of current methods by using over 8,000 genetic markers. Preliminary studies indicate sensitivity rates between 94% and 100% for detecting AMR markers. A paid early access program has signed five public health organizations. This initiative supports OpGen's commercial strategies in pathogen and AMR surveillance, showcasing potential for improved diagnostic capabilities.